MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
AbbVie Operating Income 2011-2025 | ABBV
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income AbbVie
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.14 B | 12.8 B | 18.1 B | 17.9 B | 11.4 B | 13 B | 6.38 B | 9.54 B | 9.34 B | 7.54 B | 3.41 B | 5.66 B | 5.82 B | 3.62 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 18.1 B | 3.41 B | 9.54 B |
Quarterly Operating Income AbbVie
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.9 B | 4.89 B | 3.73 B | 3.83 B | 4 B | 2.8 B | 2.28 B | 4.51 B | 2.77 B | - | 4.6 B | 3.3 B | 4.72 B | - | 4.31 B | 4.44 B | 4.1 B | - | 3.26 B | 752 M | 3.6 B | - | 2.62 B | 3.4 B | 3.01 B | - | 3.16 B | 2.76 B | 2.9 B | - | 2.69 B | 2.66 B | 2.41 B | - | 2.36 B | 2.39 B | 2.28 B | - | 1.88 B | 1.85 B | 1.69 B | - | 960 M | 1.52 B | 1.35 B | - | 1.37 B | 1.45 B | 1.3 B | - | 1.6 B | 1.42 B | 978 M | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4.89 B | 752 M | 2.71 B |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aptevo Therapeutics
APVO
|
-24.6 M | $ 0.58 | -4.5 % | $ 160 K |  USA |
 |
Aclaris Therapeutics
ACRS
|
-142 M | $ 3.02 | -0.5 % | $ 233 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-241 M | $ 1.93 | 15.56 % | $ 492 M |  Britain |
 |
Alpine Immune Sciences
ALPN
|
-58.1 M | - | - | $ 2.17 B | USA |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M |  France |
 |
BioVie
BIVI
|
-18.1 M | $ 1.17 | -3.31 % | $ 1.73 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-209 M | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
-11.5 M | - | 1.93 % | $ 17.4 M | USA |
 |
AlloVir
ALVR
|
-65.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ascendis Pharma A/S
ASND
|
-452 M | $ 211.71 | 1.31 % | $ 5 B |  Danmark |
 |
Ampio Pharmaceuticals
AMPE
|
-33.3 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
-127 M | - | - | $ 10.1 M | USA |
 |
Avenue Therapeutics
ATXI
|
-11.3 M | - | -52.27 % | $ 4.45 M | USA |
 |
AVROBIO
AVRO
|
10.2 M | - | 1083.1 % | $ 745 M | USA |
 |
BioDelivery Sciences International
BDSI
|
37.1 M | - | -4.8 % | $ 255 M | USA |
 |
Athersys
ATHX
|
-87.1 M | - | 3.77 % | $ 22.4 M | USA |
 |
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
-27 M | - | -9.72 % | $ 5.89 M | USA |
 |
Acasti Pharma
ACST
|
-16.7 M | - | 4.01 % | $ 150 M |  Canada |
 |
Can-Fite BioPharma Ltd.
CANF
|
-8.13 M | $ 0.17 | -18.86 % | $ 370 M |  Israel |
 |
Adaptimmune Therapeutics plc
ADAP
|
-140 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Berkeley Lights
BLI
|
-98.1 M | - | -7.31 % | $ 87 M | USA |
 |
Catalyst Biosciences
CBIO
|
-67.2 M | $ 12.35 | - | $ 813 M | USA |
 |
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | USA |
 |
BioNTech SE
BNTX
|
15.3 B | $ 95.26 | 0.78 % | $ 27.2 B | Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
205 M | $ 26.97 | -0.55 % | $ 1.31 B | USA |
 |
BeiGene, Ltd.
BGNE
|
-568 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Calithera Biosciences
CALA
|
-115 M | - | -10.95 % | $ 876 K | USA |
 |
Certara
CERT
|
-1.73 M | $ 8.85 | -0.51 % | $ 1.42 B | USA |
 |
Anika Therapeutics
ANIK
|
-87.6 M | $ 9.55 | - | $ 140 M | USA |
 |
bluebird bio
BLUE
|
-244 M | - | - | $ 546 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
-624 M | - | -6.81 % | $ 3.04 B | USA |
 |
Acer Therapeutics
ACER
|
-24.6 M | - | 2.71 % | $ 14 M | USA |
 |
Cellectis S.A.
CLLS
|
-131 M | $ 4.99 | 5.05 % | $ 116 M | France |
 |
Axon Enterprise
AXON
|
58.5 M | $ 580.59 | -0.56 % | $ 44 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-37.5 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-7.83 M | $ 2.58 | 5.16 % | $ 16.2 M | USA |
 |
ChromaDex Corporation
CDXC
|
7.73 M | - | -0.88 % | $ 598 M | USA |
 |
AstraZeneca PLC
AZN
|
1.06 B | $ 92.72 | -0.19 % | $ 96.9 B | Britain |
 |
Acorda Therapeutics
ACOR
|
-265 M | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
-6.36 M | - | -5.38 % | $ 6.06 M | USA |
 |
Burford Capital Limited
BUR
|
242 M | $ 9.27 | 1.93 % | $ 1.49 B | Britain |
 |
Celldex Therapeutics
CLDX
|
-195 M | $ 25.94 | -1.74 % | $ 1.67 M | USA |